Furthermore, combination of BRAF inhibitors and MEK inhibitors upregulates melanoma antigens and HLA class I molecules in BRAF-mutant melanoma cell lines as demonstrated by Liu et al. (135). Here, MAP2K7 is linked to melanoma.